Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateLouisianaEnacted
HB 870: INSURANCE/HEALTH: Provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars (EN NO IMPACT See Note)
Chris Turner
HB 870 status: Enacted — Signed by the Governor. Becomes Act No. 907 (updated Jun 12, 2026).
Source
OpenStates
Confidence
Low
Analysis basis
OpenStates summary
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
78OUT OF 100
Score:78/100 civic fit
Risk:Low Risk
Impact:Moderate Impact 50/100
Constitutionality95%
Bipartisan70%
Public opinion85%
Bill summary
What changes
The bill updates regulatory standards for health insurance companies in Louisiana, specifically targeting how generic drugs and biosimilars are placed on formularies and how cost-sharing (copays/deductibles) is structured for these items.
Who is affected
Louisiana residents with health insurance plans, health insurance providers operating in the state, and patients relying on generic or biosimilar medications.
Requirements and enforcement
Insurers must adjust their drug formulary placement and cost-sharing requirements to favor cheaper generic and biosimilar alternatives.
Costs and funding
The bill does not cost the state government any additional money; costs are limited to private sector administrative compliance.
When it takes effect
The bill was signed by the Governor on June 12, 2026, becoming Act No. 907.
Potential benefits
Primary benefits include lower out-of-pocket expenses for consumers, improved access to affordable medication, and increased utilization of biosimilars.
Risks and tradeoffs
Potential for insurers to redistribute costs elsewhere in premium structures and uncertainty regarding the impact on manufacturer rebate programs.
What is still unknown
The specific formulary structures insurers will adopt to remain compliant and the exact scale of savings for individual policyholders.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Positive outlook
75%
Benefits
- Reduced out-of-pocket costs for consumers purchasing generic drugs
- Standardized formulary requirements across insurance providers
- Increased market accessibility for biosimilar medications
Risks
- Potential for insurance carriers to adjust premiums to offset reduced cost-sharing
- Operational compliance costs for insurance entities modifying formularies
- Possible administrative burden during the transition to new placement rules
Society
Positive outlook
80%
Benefits
- Improved health equity through better medication affordability
- Higher patient adherence to medication regimens due to lower cost
- Reduced financial stress for households reliant on prescription therapy
Risks
- Risk of insurance plan redesigns impacting other covered benefits
- Uncertainty regarding long-term formulary stability for patients
- Dependence on insurer compliance to realize promised savings
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Public Health & Safety
Positive outlook
80%
Benefits
- Enhanced access to life-sustaining medications through cost reduction
- Increased utilization of FDA-approved generic and biosimilar drugs
- Potential for improved health outcomes linked to better medication access
Risks
- Potential shifts in medical treatment options based on insurer cost-incentives
- Risk that cost-sharing changes do not address supply chain availability
- Dependence on clinical efficacy of cheaper alternatives
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
OpenStates
Official bill text or data from OpenStates.
Confidence
Low
Information is limited or incomplete.
Analysis basis
OpenStates summary
Source used for this bill's analysis.
Source note
LegiScan returned a PDF-only document. PDF extraction is not enabled in this build, so the pipeline used a safer fallback.
Analysis scope
Source material limited to a brief summary from OpenStates.
04
Where it stands
Official recordSigned by the Governor. Becomes Act No. 907.
- IntroducedComplete
- CommitteeComplete
- Chamber votesComplete
- Final agreementComplete
- GovernorComplete
- EnactedComplete
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.